Ryanodine receptor mutations in arrhythmias: advances in understanding the mechanisms of channel dysfunction

N L Thomas1, C H George, A J Williams

  • 1Department of Cardiology, Wales Heart Research Institute, Cardiff University School of Medicine, Cardiff CF14 4XN, U.K. thomasnl1@cardiff.ac.uk

Insights

Mutations in the cardiac ryanodine receptor (RyR2) channel cause sudden cardiac death by disrupting calcium release. Research explores multiple mechanisms, including phosphorylation and altered calcium sensing, to understand RyR2 dysfunction.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • The cardiac ryanodine receptor (RyR2) is crucial for myocyte contraction via excitation-contraction (EC) coupling.
  • Mutations in RyR2 can lead to triggered arrhythmias and sudden cardiac death (SCD).

Purpose of the Study:

  • To review recent mechanistic developments in understanding RyR2 dysfunction in SCD.
  • To explore various candidate mechanisms contributing to aberrant sarcoplasmic reticulum (SR) Ca(2+) release.

Main Methods:

  • Analysis of recent studies on RyR2 mutations.
  • Inclusion of data from mutant RyR2 transgenic mouse models.
  • Consideration of peptide-probe studies and functional/phenotypic heterogeneity.

Main Results:

  • Multiple mechanisms, including defective phosphorylation, altered protein binding, and disrupted Ca(2+) sensing, are implicated in RyR2 dysfunction.
  • A single common mechanism is unlikely to explain all cases of mutant RyR2 dysfunction.
  • Functional and phenotypic heterogeneity of RyR2 mutations contribute to diverse disease phenotypes.

Conclusions:

  • Understanding the complex mechanisms of RyR2 dysfunction is vital for addressing SCD.
  • Further research is needed to elucidate the specific contributions of each mechanism to RyR2-linked arrhythmias.
  • Individualized approaches may be necessary to manage SCD risk associated with RyR2 mutations.

Related Concept Videos

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Voltage-gated Ion Channels01:26

Voltage-gated Ion Channels

Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...